Birlasoft Targets 30–40% Sales Growth, Sees FY27 Better

Birlasoft Limited — Q4 & FY26 Earnings Call (held 06 May 2026)

1. Overall Tone of Management: Neutral (leaning Optimistic)

• Management repeatedly highlights “soft demand environment” and “uncertainty” (macro headwinds, client-specific issues, discretionary spend).
• However, they also emphasize margin strength, AI-led deal wins, and a clear growth-engine reset (sales hiring, new leadership, “AI First” delivery changes).
• Guidance is still avoided, but confidence language is stronger than in earlier calls (“bad news is behind us”, “confidence as we start the new financial year”).

2. Key Themes from Management Commentary

• Demand softness + client-specific drag (Life Sciences/MedTech manufacturing-oriented):
• “very soft demand environment… leading to some client-specific issues and… erosion of revenue.”
• CFO cites an operational issue at a customer and fewer working days.
• AI-led transformation as the growth lever:
• Continued investment in Cogito and “agentic AI” / smart agents.
• Examples: MedTech multi-domain modernization; BFSI GenAI scaling in North American P&C.
• Margin expansion via “quality of revenue” and cost optimization:
• They attribute EBITDA margin expansion to walking away from non-profitable revenue streams and operational efficiencies.
• Q4 EBITDA margin: 18.5%; FY26 EBITDA margin: 16.3% (333 bps expansion).
• Growth engine reset focused on sales + pipeline/order booking:
• Major hiring: expect sales team up 30–40% YoY by mid-FY27.
• “AI First” operating model changes in delivery mechanism to show benefits in coming quarters.
• Explicit strategic focus going forward: “only… centered around sales, pipeline generation, and order booking.”
• Leadership and capability build-out:
• New COO (Vikram Puranik), ERP leader (SAP veteran), Data & AI leader, ERP leader, Life Sciences vertical leader, Americas leader already added earlier.

3. Q&A Analysis

Theme A: FY27 growth trajectory & sequencing (H1 vs H2)

• Core questions
• Will FY27 growth be positive? How will growth play out across quarters?
• Is H1 softer and H2 better (order booking vs revenue)?
• Management response
• No guidance on revenue, but they expect pipeline/order book improvement from sales ramp and leadership changes.
• “Bad news is behind us” and “FY’27 will be better for us.”
• H1 order booking typically soft; H2 better: “I don’t see that changing.”
• Notable / evasive elements
• Revenue sequencing is repeatedly softened: “hard to say at this stage.”
• They lean on order booking → revenue causality rather than giving a measurable revenue path.

Theme B: Sales ramp impact on margins (SG&A vs EBIT)

• Core questions
• Will higher sales hiring dilute FY27 margins? What is sustainable margin?
• Management response
• CFO reiterates “steady-state EBITDA margin… in the 15% range.”
• Acknowledges margin erosion from investments and front-ending productivity benefits.
• Strong/clear answer
• They provide a framework: investments + productivity front-ending → near-term margin pressure, but 15%+ sustainable.

Theme C: Life Sciences/Manufacturing client-specific issue—extent and whether behind

• Core questions
• Which vertical/client had the operational issue?
• Is it fully behind and will it recur?
• Management response
• Confirmed: Life Sciences → MedTech/manufacturing-oriented.
• CEO: “intuitively feel that the bad news… is behind us… client-specific… very client-specific… turnaround.”
• Evasive/partial
• “I can’t delve into too much” and “we don’t know what we don’t know” leaves recurrence risk unquantified.

Theme D: TCV / net new order booking softness & deal slippage

• Core questions
• Why is net new TCV soft in Q4? Any slippage into June?
• What deal intake is needed for sustainable QoQ growth?
• Management response
• Net new soft because clients are delaying decision-making; deals pushed to Q1 rather than lost.
• CEO: focus is converting pipeline; cannot give exact deal intake numbers.
• CFO: Q4 order booking above $200m; net new is soft but not “anything more to read.”
• Notable
• They explicitly quantify one factor: ~200 bps of FY26 growth went away due to walking away from low-margin/non-strategic deals (asked by Dipesh).

Theme E: ERP outlook and competitive/AI narrative (Palantir/SAP compression)

• Core questions
• Is ERP being compressed by AI competition (Palantir/SAP migration concerns)?
• Will ERP improve materially with new leadership?
• Management response
• ERP “very challenged” irrespective of Palantir; now they have an ERP leader (SAP veteran in New York).
• “System of records is not going away” and they see long-term potential; monitoring Palantir but client conversations show interest across ERP landscape.
• Strong
• Clear stance: ERP demand not structurally collapsing; leadership change is the near-term catalyst.

Theme F: Outcome-based / fixed-price AI deals—impact on revenue timing

• Core questions
• Are outcome-based deals fixed price? Upside/downside?
• How does productivity deflation affect revenue growth timing?
• Management response
• Outcome-based = operational outcomes, fees linked to outcomes; typically fixed price.
• They admit: revenue deflation “in immediate and medium term” because savings are underwritten upfront; revenue “catching up” later.
• Credibility signal
• They explain the mechanism rather than denying revenue timing effects.

4. Guidance / Outlook

Explicit guidance (quantitative)

• Sales hiring target: by mid-FY27, sales team strength up 30%–40% YoY.
• Margin expectation: CFO states steady-state EBITDA margin ~15% range (and “upward of 15%” as investments ramp; erosion from current levels expected).
• ETR normalization: CFO says elevated ETR provision is limited to FY26; expects ETR to settle closer to historical starting FY27.
• DSO clarification: reported DSO 62 days; adjusted DSO would have been 55 days if collections through 3 April are considered.

Implicit signals (qualitative)

• FY27 growth: “hoping… bad news is behind us” and “FY’27 will be better,” but no revenue guidance due to volatility.
• Order booking conversion focus: “pipeline fixed… order booking… revenues will automatically follow.”
• Client-specific issue: CEO “intuitively feels” it won’t recur, but acknowledges uncertainty.
• AI-first operating model benefits: delivery mechanism changes should show benefits “over the next couple of quarters.”

5. Standout Statements (direct / high-signal)

• Demand + revenue erosion admission:
• “very soft demand environment… leading to some client-specific issues and as a result, erosion of revenue.”
• Margin/cost narrative with strategic pruning:
• “walking away from several non-profitable revenue streams that affected our overall revenue but contributed to our margin expansion.”
• Growth engine reset (sales + AI-first):
• “By the middle of FY ’27… sales team strength would have gone up by 30% to 40%… pivot to a growth-oriented ‘AI First’ organization.”
• No guidance but directional confidence:
• “we are hoping that the bad news is behind us now and FY’27 will be better for us.”
• Mechanism for revenue deflation in AI deals:
• “we have to commit to the savings and underwrite some of the savings right up front, which is why you see revenue deflation in the immediate and the medium term.”
• ERP stance vs AI disruption:
• “System of records is not going away.”
• Client issue localization:
• “It is Life Sciences… MedTech sector… manufacturing-orientated.”

6. Red Flags / Positive Signals

Red flags
– No revenue guidance despite repeated “turnaround” framing; relies on order booking conversion.
– Client-specific risk not fully quantified (“can’t delve into too much”; “we don’t know what we don’t know”).
– Net new TCV softness acknowledged; management says “not lost, pushed,” but timing risk remains.
– Margin support partly from one-offs/currency tailwinds (CFO notes one-offs and FX benefits; sustainability depends on execution + investments).

Positive signals
– Sustained margin improvement: FY26 EBITDA margin 16.3% vs 13% in FY25.
– Order booking momentum: Q4 TCV $208m and “second quarter in a row” above $200m.
– Clear operational discipline: rationalization of tail accounts, cost optimization, cash generation.
– Sales capacity expansion + leadership depth (COO + ERP + Data/AI + partnerships + Life Sciences leader).

7. Historical Comparison & Consistency Analysis (vs prior 3–4 calls)

a. Change in Tone Over Time

• Earlier calls (Q1 FY26, Q2 FY26, Q3 FY26): tone was more cautiously optimistic with emphasis on sequential growth and margin improvements; still acknowledged macro and manufacturing headwinds.
• Current call (Q4 FY26): tone is more “turnaround + investment” focused:
• Stronger emphasis on sales ramp (30–40% YoY) and AI-first delivery changes.
• Still admits revenue erosion and volatility, but management confidence language is more direct (“bad news behind us”).
• Classification shift: More Optimistic than Q1/Q2, but still not fully confident enough to provide guidance.

b. Tracking Past Commitments vs Outcomes

• Past statement (Q3 FY26 call, Jan 28 2026):
• “On the deals front… TCV… $202 million… nearly half… new engagements…”
• Also: “steady-state EBITDA margin… about 15%.”
• What happened by Q4 FY26 (current call):
• EBITDA margin exceeded expectations: Q4 18.5%, FY26 16.3% (15% steady-state still referenced).
• Deal signings: Q4 TCV $208m, second quarter above $200m.

• Assessment: ✅ Delivered on margin steadiness/expansion and deal signing momentum (though revenue growth still weak).

• Past statement (Q2 FY26 call, Nov 6 2025):

• Expect “second half… better than first half… sequential revenue growth in Q3 and Q4.”
• Outcome by FY26 (current call):
• FY26 revenue still down -1.2% rupee and -6% dollar; sequential growth did not translate into full-year growth.

• Assessment: ❌ Missed / not delivered at full-year level (even if some quarters improved).

• Past statement (Q1 FY26 call, Aug 7 2025):

• Focus on order book; hope for sequential growth in Q2 and then Q3/Q4 depending on furloughs.
• Outcome by FY26:
• Revenue remained challenged for multiple quarters; management now explicitly says “6 quarters… not grown” (analyst question, CEO agrees).
• Assessment: ⏳ Delayed (growth recovery took longer than implied).

c. Narrative Shifts

• From “margin + operational efficiency” to “growth engine reset”:
• Earlier calls: margin improvements were the main proof point while revenue was “wait-and-watch.”
• Now: they explicitly pivot to sales hiring + AI-first operating model as the central lever.
• ERP narrative evolves:
• Earlier: ERP lagged and was tied to manufacturing; “cycle will take a couple of quarters.”
• Now: ERP is “very challenged” but they claim a leadership fix and “system of records is not going away.”
• Outcome-based AI deals become more central:
• Earlier: AI-led capabilities and agentic AI wins.
• Now: they provide a revenue timing explanation (underwrite savings → medium-term revenue deflation).

d. Consistency & Credibility Signals

• Credibility: Medium
• Positives: they quantify margin mechanics (FX + one-offs + steady-state) and explain AI deal economics.
• Concerns: repeated “bad news behind us / turnaround soon” without revenue guidance; revenue has remained weak across many quarters.
• They acknowledge misses more directly now (“we are pretty disappointed… 6 quarters, we’ve not grown”).

e. Evolution of Key Themes

• Demand/macro: Deteriorating/volatile throughout; still unresolved.
• Margins: Improving/stabilizing (steady-state 15% framework maintained; actuals above steady-state).
• Growth/demand conversion: Still deteriorating in revenue terms; order booking improved but revenue lag persists.
• AI transformation: Increasingly framed as both delivery capability and commercial model affecting revenue timing.

f. Additional Insights (cross-period)

• Revenue weakness is increasingly attributed to “AI productivity deflation” mechanics, not only macro or client issues—this is a subtle but important shift in narrative.
• Management is using margin strength to justify investment capacity (“we have the money to invest in sales”), implying they view margin as a temporary buffer while growth engine ramps.
• Client-specific issues are now localized to Life Sciences/MedTech manufacturing, suggesting other verticals (notably BFSI/E&U) are comparatively healthier—yet net new TCV softness indicates pipeline timing risk remains.